Clinical Trial Update: Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study [Phase 2]

View source ↗

Summary

An exploratory Phase II trial evaluating tislelizumab plus nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer with bone metastase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Triple-negative Breast Cancer, Bone Metastases | Phase 2 | Status: RECRUITING